# Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma

> **NCT07175441** · PHASE2 · RECRUITING · sponsor: **Riboscience, LLC.** · enrollment: 220 (estimated)

## Conditions studied

- Advanced Unresectable Hepatocellular Carcinoma

## Interventions

- **DRUG:** RBS2418
- **DRUG:** STRIDE (durvalumab + tremelimumab)

## Key facts

- **NCT ID:** NCT07175441
- **Lead sponsor:** Riboscience, LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-10
- **Primary completion:** 2027-04
- **Final completion:** 2027-08
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07175441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07175441, "Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07175441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*